Tanaka Hiroaki, Yamakoshi Yoshihito, Sakimura Chie, Mori Takuya, Deguchi Sota, Miki Yuichiro, Yoshii Mami, Tamura Tatsuro, Toyokawa Takahiro, Muguruma Kazuya, Ohira Masaichi
Dept. of Gastroenterological Surgery, Osaka City University Graduate School of Medicine.
Gan To Kagaku Ryoho. 2020 Sep;47(9):1292-1297.
Currently, the immunotherapy approved for gastric cancer is immune checkpoint blockade( ICB) therapy. The effects of ICB depend on the T cell-mediated immune response elicited at the cancer site. Based on the results of previous clinical trials, it is clear that an enhanced immune response to cancer improves prognosis. Thus, the development of biomarkers to predict local immune responses may increase the significance of future immunotherapy for gastric cancer. Biomarker research has clearly progressed with the rapid development of genetic analysis technologies, enabling the analysis of data from clinical trials. Not only the molecular biomarkers known to date for ICB biomarkers, but immune cells that influence ICB therapy are also reviewed in this article.
目前，已获批用于胃癌治疗的免疫疗法是免疫检查点阻断（ICB）疗法。ICB的疗效取决于在癌症部位引发的T细胞介导的免疫反应。根据以往临床试验的结果，很明显，增强对癌症的免疫反应可改善预后。因此，开发预测局部免疫反应的生物标志物可能会提高未来胃癌免疫疗法的重要性。随着基因分析技术的迅速发展，生物标志物研究取得了明显进展，使得对临床试验数据的分析成为可能。本文不仅对迄今已知的ICB生物标志物分子生物标志物进行了综述，还对影响ICB治疗的免疫细胞进行了综述。
